Inherent Biosciences Raises Series A to Raise Standard of Care in Male Reproductive Health


Salt Lake City – Inherent Biosciences, the first Utah company involved in commercializing a diagnostic in the emerging biotech field of epigenetics, has raised Series A funding from a Propel-led investor group Los Angeles-based Bio Partners toward Inherent’s goal of changing the course of reproductive health.

Inherent seeks to redefine the path to parenthood by raising the bar for male reproductive health through the commercialization of an epigenetic sperm quality test (Path SpermQT).

Inherent’s focus on epigenetics is seen by Leen Kawas, Ph.D., Managing Partner of Propel, as an ideal example of its venture capital funds’ focus on the startup goal. biotech to help founders and management teams “fulfill the urgent mission of advancing human health with disruptive technologies”. technologies.”

“Inherent Biosciences is at the forefront of disruptive platform technology in epigenetics with the potential to advance not only the pathway to parenthood, but several other unmet clinical needs,” added Kawas.

Many stakeholders, from patients to physicians and reproductive health executives, also participated in the round, which included investments from Portfolia’s FemTech II fund as well as the Alliance of Angels.

Epigenetics is the study of heritable changes that do not involve alterations in DNA sequence, which is the traditional genetic basis of heredity. Thus, epigenetics involves characteristics “on top of” this traditional genetic basis of heredity.

“The path to parenthood takes both an egg and a sperm and deserves the best of science,” says Kristin Brogaard, co-founder and chief scientific officer of Inherent Biosciences. “Much of the burden falls on women and yet up to half of infertility is due to male factors. Understanding the unique biology of egg and sperm can make more informed plans for the journey of fertility.

The funding will allow Inherent to expand its pipeline, expand its commercial operations, and generate the additional seminal data needed to add SpermQT to the standard of care.

Inherent Biosciences’ team of epigenetic technology innovators is comprised of experienced entrepreneurs, clinicians and scientists working directly with the nation’s top male fertility leaders, including Dr. Larry Lipshultz, Professor of Urology and Chief of the Scott Division of the Department of Urology. male reproductive medicine at Baylor College of Medicine; Dr. James Smith, director of the Male Reproductive Health Center at UCSF; and Dr. Jim Hotaling, director of the University of Utah Men’s Health Program and current president of the Society for the Study of Male Reproduction, the first society in the field.

“Portfolia is pleased to invest in Inherent Biosciences as they use advanced genetic technology to help analyze sperm, addressing the other half of the fertility problem,” said Nola Masterson, lead investor in FemTech I and II funds. Portfolio.

Andy Olson, co-founder and CEO of Inherent Biosciences, explained why the company decided to focus on fertility: “I have friends who have been trying to get pregnant for years, spent thousands of dollars, mostly out of pocket, and were told they had unexplained fertility issues.” ‘ infertility. They are not alone, 30% of infertilities are unexplained. Now is the time for innovation in men’s reproductive health, and we’re on a mission to elevate the standard of care.

Olson continued, “This new funding, including access to the Propel Bio Partners ecosystem and network of experts and advisors, will enable us to significantly expand our business operations while generating the foundational data needed to add SpermQT to standard of care. We are excited to grow our team, spread the word about our groundbreaking technology, and build industry-wide partnerships to help patients have a better parenting experience.


Comments are closed.